Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Gaush Meditech is a leading distributor of ophthalmic medical device in China. The company is looking to raise up to USD 200m via a Hong Kong listing.</li>
<li>We look at the company's key segments and products. The company's story of being a comprehensive distributor and R&amp;D does not impress us.</li>
<li>The company is mainly held by the founder's family. We think the company should be valued as a distributor and not innovative medical device company.</li>
</ul>


Gaush Meditech is a leading distributor of ophthalmic medical device in China. The company is looking to raise up to USD 200m via a Hong Kong listing.
We look at the company's key segments and products. The company's story of being a comprehensive distributor and R&amp;D does not impress us.
The company is mainly held by the founder's family. We think the company should be valued as a distributor and not innovative medical device company.


Gaush Meditech (高视医疗科技) Pre-IPO: Need a Very Convincing Story